DE60329165D1 - Detektion und/oder beobachtung von synuclein-assoziierten krankheiten - Google Patents
Detektion und/oder beobachtung von synuclein-assoziierten krankheitenInfo
- Publication number
- DE60329165D1 DE60329165D1 DE60329165T DE60329165T DE60329165D1 DE 60329165 D1 DE60329165 D1 DE 60329165D1 DE 60329165 T DE60329165 T DE 60329165T DE 60329165 T DE60329165 T DE 60329165T DE 60329165 D1 DE60329165 D1 DE 60329165D1
- Authority
- DE
- Germany
- Prior art keywords
- synuclein
- observation
- detection
- associated diseases
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0203446.0A GB0203446D0 (en) | 2002-02-14 | 2002-02-14 | Detection and/or monitoring of synuclein-related diseases |
PCT/GB2003/000677 WO2003069332A2 (en) | 2002-02-14 | 2003-02-14 | Detection and/or monitoring of synuclein-related diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60329165D1 true DE60329165D1 (de) | 2009-10-22 |
Family
ID=9931023
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60329165T Expired - Lifetime DE60329165D1 (de) | 2002-02-14 | 2003-02-14 | Detektion und/oder beobachtung von synuclein-assoziierten krankheiten |
Country Status (9)
Country | Link |
---|---|
US (1) | US20050176078A1 (de) |
EP (1) | EP1476758B2 (de) |
JP (1) | JP2005528588A (de) |
AT (1) | ATE442592T1 (de) |
AU (1) | AU2003214364A1 (de) |
CA (1) | CA2480466C (de) |
DE (1) | DE60329165D1 (de) |
GB (1) | GB0203446D0 (de) |
WO (1) | WO2003069332A2 (de) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040146521A1 (en) * | 1999-06-01 | 2004-07-29 | Schenk Dale B. | Prevention and treatment of synucleinopathic disease |
US9034337B2 (en) | 2003-10-31 | 2015-05-19 | Prothena Biosciences Limited | Treatment and delay of outset of synucleinopathic and amyloidogenic disease |
US20080014194A1 (en) * | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
US8506959B2 (en) * | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
TW200509968A (en) * | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
US8697082B2 (en) * | 2002-11-01 | 2014-04-15 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
US7358331B2 (en) * | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
US7674599B2 (en) * | 2003-11-08 | 2010-03-09 | Elan Pharmaceuticals, Inc. | Methods of using antibodies to detect alpha-synuclein in fluid samples |
DE10361258A1 (de) | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson |
DE102004014841B4 (de) | 2004-03-24 | 2006-07-06 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms |
ES2310057B1 (es) * | 2004-07-19 | 2009-11-17 | Oryzon Genomics, S.A. | Metodo de analisis molecular y tratamiento en demencia de cuerpos de lewy. |
CN1752104B (zh) * | 2004-09-21 | 2010-05-05 | 北京市肿瘤防治研究所 | 突触蛋白γ的单克隆抗体及其应用 |
WO2007011907A2 (en) * | 2005-07-19 | 2007-01-25 | University Of Rochester | Alpha-synuclein antibodies and methods related thereto |
IL199534A (en) | 2007-01-05 | 2013-01-31 | Univ Zuerich | An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses. |
US8147833B2 (en) * | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
EP2118300B1 (de) * | 2007-02-23 | 2015-05-27 | Prothena Biosciences Limited | Verhinderung und behandlung synukleinopathischer und amyloidogener krankheiten |
GB0716885D0 (en) | 2007-08-30 | 2007-10-10 | United Arab Emirates Universit | Diagnostic agent |
JP5810413B2 (ja) | 2008-12-19 | 2015-11-11 | バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー | ヒト抗アルファシヌクレイン自己抗体 |
WO2011033252A1 (en) * | 2009-09-16 | 2011-03-24 | United Arab Emirates University | Diagnostic agent for parkinson's disease |
CN101692092B (zh) * | 2009-09-24 | 2013-04-10 | 首都医科大学宣武医院 | 定量检测人血清中自体α-突触核蛋白抗体的方法 |
US10989718B2 (en) * | 2014-09-11 | 2021-04-27 | Amprion, Inc. | Detection of misfolded alpha synuclein protein |
WO2012061789A2 (en) * | 2010-11-05 | 2012-05-10 | Brandeis University | Tetrameric alpha-synuclein and use thereof |
WO2012061786A1 (en) * | 2010-11-05 | 2012-05-10 | Brandeis University | Ice cleaved alpha-synuclein a biomarker |
WO2012074882A2 (en) * | 2010-11-24 | 2012-06-07 | Elan Pharmaceuticals, Inc. | Phagocytic activity as a marker of synucleinopathic disease |
WO2012177972A1 (en) | 2011-06-23 | 2012-12-27 | Biogen Idec International Neuroscience Gmbh | Anti-alpha synuclein binding molecules |
JP6263473B2 (ja) * | 2011-11-02 | 2018-01-31 | バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー | 脳における高レベルのα−シヌクレインを診断するための抗α−シヌクレイン抗体の使用 |
ES2481517B1 (es) * | 2013-01-29 | 2015-06-01 | Universidad De Sevilla | Método para el diagnóstico de la enfermedad de parkinson en estadios tempranos |
HRP20231232T1 (hr) * | 2014-09-11 | 2024-01-19 | Board Of Regents Of The University Of Texas System | Otkrivanje pogrešno savijenih proteina |
WO2016075516A1 (en) | 2014-11-14 | 2016-05-19 | United Arab Emirates University | Compounds for use as imaging agents |
MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
CN104711280B (zh) * | 2014-12-10 | 2018-04-13 | 中国医学科学院医学生物学研究所 | 表达和纯化同时缺失外显子3和5 的α突触核蛋白选择性剪切体蛋白的方法 |
MX2019013589A (es) | 2017-05-16 | 2020-07-20 | Claudio Soto Jara | Deteccion de proteina tau con plegamiento incorrecto. |
IL271359B2 (en) * | 2017-06-19 | 2023-11-01 | Kainos Medicine Inc | Modulators of alpha-synuclein |
SG11202001281WA (en) | 2017-08-22 | 2020-03-30 | Biogen Ma Inc | Pharmaceutical compositions containing anti-beta amyloid antibodies |
JP7173532B2 (ja) * | 2018-08-28 | 2022-11-16 | 学校法人順天堂 | α-シヌクレイノパチーの診断 |
RU2703430C1 (ru) * | 2018-12-13 | 2019-10-16 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр глазных болезней имени Гельмгольца" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ГБ им. Гельмгольца" Минздрава России) | Способ прогнозирования развития нейродегенеративных заболеваний, в основе патогенеза которых лежит гамма-синуклеинопатия |
EP3779448A1 (de) * | 2019-08-12 | 2021-02-17 | Baden-Württemberg Stiftung gGmbH | Neuartiger diagnostischer marker für die creutzfeldt-jakob-krankheit und morbus-alzheimer |
EP4111197A1 (de) * | 2020-02-25 | 2023-01-04 | Markus Otto | Diagnose einer mit synaptischer degeneration assoziierten erkrankung mittels elisa zur bestimmung einer beta-synuklein-konzentration in csf |
EP4252243A2 (de) | 2020-11-30 | 2023-10-04 | Enigma Biointelligence, Inc. | Nichtinvasive beurteilung von morbus alzheimer |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5602042A (en) * | 1994-04-14 | 1997-02-11 | Cytyc Corporation | Method and apparatus for magnetically separating biological particles from a mixture |
WO1999050300A1 (en) * | 1998-03-30 | 1999-10-07 | The Trustees Of The University Of Pennsylvania | Method of identifying, diagnosing and treating synuclein positive neurodegenerative disorders |
ATE312349T1 (de) * | 1998-07-03 | 2005-12-15 | Innogenetics Nv | Differentielle diagnose von neurodegeneration |
JP2004502781A (ja) * | 2000-07-07 | 2004-01-29 | パナシア ファーマシューティカルズ インコーポレーテッド | 神経組織の損傷を予防するため、およびα−シヌクレイン疾患を処置するための方法 |
AU2002239765A1 (en) * | 2000-11-03 | 2002-06-03 | Proteotech, Inc. | Antibody pti-hs7 for treatment of alzheimer's disease and other amyloidoses and parkinson's disease |
-
2002
- 2002-02-14 GB GBGB0203446.0A patent/GB0203446D0/en not_active Ceased
-
2003
- 2003-02-14 DE DE60329165T patent/DE60329165D1/de not_active Expired - Lifetime
- 2003-02-14 CA CA2480466A patent/CA2480466C/en not_active Expired - Fee Related
- 2003-02-14 AT AT03709934T patent/ATE442592T1/de not_active IP Right Cessation
- 2003-02-14 JP JP2003568402A patent/JP2005528588A/ja active Pending
- 2003-02-14 US US10/503,416 patent/US20050176078A1/en not_active Abandoned
- 2003-02-14 WO PCT/GB2003/000677 patent/WO2003069332A2/en active Application Filing
- 2003-02-14 EP EP03709934.8A patent/EP1476758B2/de not_active Expired - Lifetime
- 2003-02-14 AU AU2003214364A patent/AU2003214364A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
GB0203446D0 (en) | 2002-04-03 |
ATE442592T1 (de) | 2009-09-15 |
WO2003069332A3 (en) | 2004-01-08 |
EP1476758B2 (de) | 2015-02-11 |
JP2005528588A (ja) | 2005-09-22 |
EP1476758B1 (de) | 2009-09-09 |
AU2003214364A1 (en) | 2003-09-04 |
WO2003069332A2 (en) | 2003-08-21 |
CA2480466C (en) | 2010-12-21 |
EP1476758A2 (de) | 2004-11-17 |
US20050176078A1 (en) | 2005-08-11 |
CA2480466A1 (en) | 2003-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60329165D1 (de) | Detektion und/oder beobachtung von synuclein-assoziierten krankheiten | |
DE60331921D1 (de) | Diagnose und prävention der krebszellinvasion | |
DE60108230D1 (de) | Vorrichtung für diagnose und behandlung von arrhytmien | |
DE60326214D1 (de) | Assays zur überwachung von krebspatienten auf grundlage der spiegel von analytenkomponenten des plasminogen-aktivator-systems in proben von körperflüssigkeiten | |
DE60312309D1 (de) | Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten | |
CY1110503T1 (el) | Πενταμιδινη για θεραπεια καρκινου | |
MX2009005941A (es) | Ensayos de diagnostico complementario para terapia de cancer. | |
ATE514948T1 (de) | In vitro verfahren zur diagnose von neurodegenerativen erkrankungen | |
WO2006047475A3 (en) | Detection and analysis of ophthalmically-relevant fluorescent molecules | |
ATE483982T1 (de) | Liquordiagnostisches in vitro verfahren zur diagnose von demenz-erkrankungen und neuroinflammatorischen erkrankungen | |
ATE451477T1 (de) | Diagnose und überwachung von hepatozellulärem karzinom | |
WO2006094068A3 (en) | Hdac inhibitors that promote brm expression and brm related diagnostics | |
ATE557087T1 (de) | Verfahren und kit zum nachweis von sklerose verursachenden proliferativen erkrankungen und/oder heilmittel gegen sklerose verursachende proliferative erkrankungen sowie verfahren und kit zur identifizierung einer bei der vorbeugung und/oder behandlung von sklerose verursachenden proliferativen erkrankungen wirksamen substanz | |
DE60122673D1 (de) | Methoden zur diagnose und behandlung von herzkrankheiten | |
ATE552776T1 (de) | Verfahren und vorrichtung zur überwachung eines sedierten patienten | |
ATE520987T1 (de) | Verfahren zum nachweis und/oder screening zur überwachung eines kolorektalkrebs in einem individuum | |
DE60327530D1 (de) | Plasma urotensin und menschliche herzerkrankung | |
ATE452395T1 (de) | Verfahren und vorrichtung zum kommunizieren mit beistehenden im fall eines katastrophalen persönlichen notfalls | |
AU2003272189A8 (en) | Caspase inhibitors for the treatment of diseases and conditions caused by exposure to radionuclides, biological agents, or chemical agents | |
ATE393243T1 (de) | Diagnostisches verfahren der mastozytose | |
ATE554790T1 (de) | Verfahren und zusammensetzungen zur diagnose von asthma | |
ATE397090T1 (de) | Verfahren und verbindungen zur diagnose von entzündlichen erkrankungen und identifizierung von pharmakologischen mitteln zur behandlung von entzündlichen erkrankungen | |
AU2003299389A8 (en) | PRP detection method using an aminoglycoside antibiotic | |
DE60127935D1 (de) | Verfahren zur diagnose der effektivität der xenotypischen antikörpertherapie | |
EP1492880A4 (de) | Ex-vivo-verfahren zur bestimmung der cetp-aktivität und der wirksamkeit der behandlung von herzerkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8363 | Opposition against the patent |